Inventiva (IVA) Competitors $4.32 -0.26 (-5.57%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IVA vs. BHVN, IMCR, CDTX, AUPH, WVE, JANX, EWTX, ARDX, HROW, and SPRYShould you be buying Inventiva stock or one of its competitors? The main competitors of Inventiva include Biohaven (BHVN), Immunocore (IMCR), Cidara Therapeutics (CDTX), Aurinia Pharmaceuticals (AUPH), WAVE Life Sciences (WVE), Janux Therapeutics (JANX), Edgewise Therapeutics (EWTX), Ardelyx (ARDX), Harrow (HROW), and ARS Pharmaceuticals (SPRY). These companies are all part of the "pharmaceutical products" industry. Inventiva vs. Its Competitors Biohaven Immunocore Cidara Therapeutics Aurinia Pharmaceuticals WAVE Life Sciences Janux Therapeutics Edgewise Therapeutics Ardelyx Harrow ARS Pharmaceuticals Inventiva (NASDAQ:IVA) and Biohaven (NYSE:BHVN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, valuation, institutional ownership, profitability and analyst recommendations. Which has higher earnings and valuation, IVA or BHVN? Inventiva has higher revenue and earnings than Biohaven. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInventiva$9.95M40.96-$199.34MN/AN/ABiohavenN/AN/A-$846.42M-$7.66-1.91 Which has more risk and volatility, IVA or BHVN? Inventiva has a beta of 0.73, suggesting that its share price is 27% less volatile than the S&P 500. Comparatively, Biohaven has a beta of 0.98, suggesting that its share price is 2% less volatile than the S&P 500. Do insiders and institutionals have more ownership in IVA or BHVN? 19.1% of Inventiva shares are owned by institutional investors. Comparatively, 88.8% of Biohaven shares are owned by institutional investors. 32.0% of Inventiva shares are owned by insiders. Comparatively, 16.0% of Biohaven shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Is IVA or BHVN more profitable? Inventiva's return on equity of 0.00% beat Biohaven's return on equity.Company Net Margins Return on Equity Return on Assets InventivaN/A N/A N/A Biohaven N/A -270.65%-143.70% Do analysts recommend IVA or BHVN? Inventiva currently has a consensus target price of $10.40, suggesting a potential upside of 144.13%. Biohaven has a consensus target price of $54.23, suggesting a potential upside of 270.53%. Given Biohaven's stronger consensus rating and higher probable upside, analysts clearly believe Biohaven is more favorable than Inventiva.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inventiva 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Biohaven 0 Sell rating(s) 1 Hold rating(s) 12 Buy rating(s) 2 Strong Buy rating(s) 3.07 Does the media prefer IVA or BHVN? In the previous week, Biohaven had 43 more articles in the media than Inventiva. MarketBeat recorded 44 mentions for Biohaven and 1 mentions for Inventiva. Inventiva's average media sentiment score of 1.47 beat Biohaven's score of 0.11 indicating that Inventiva is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inventiva 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biohaven 4 Very Positive mention(s) 5 Positive mention(s) 23 Neutral mention(s) 6 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryBiohaven beats Inventiva on 7 of the 13 factors compared between the two stocks. Get Inventiva News Delivered to You Automatically Sign up to receive the latest news and ratings for IVA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IVA vs. The Competition Export to ExcelMetricInventivaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$407.51M$3.11B$5.73B$9.56BDividend YieldN/A2.23%4.53%4.08%P/E RatioN/A20.4330.4625.16Price / Sales40.96238.54392.5887.62Price / CashN/A42.3737.0358.50Price / Book-3.527.918.956.21Net Income-$199.34M-$54.72M$3.26B$265.38M7 Day Performance0.95%1.66%1.06%-1.13%1 Month Performance32.71%5.89%4.31%-0.71%1 Year Performance78.99%8.72%28.40%18.86% Inventiva Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IVAInventiva3.3639 of 5 stars$4.26-7.0%$10.40+144.1%+89.3%$407.51M$9.95M0.00100Positive NewsHigh Trading VolumeBHVNBiohaven3.7896 of 5 stars$16.02+2.0%$53.75+235.5%-64.2%$1.66BN/A-2.09239Analyst ForecastIMCRImmunocore1.9622 of 5 stars$32.31-1.7%$58.00+79.5%-12.4%$1.66B$310.20M-80.78320Positive NewsCDTXCidara Therapeutics3.5373 of 5 stars$63.24-3.0%$64.14+1.4%+402.2%$1.65BN/A-5.6890AUPHAurinia Pharmaceuticals2.9781 of 5 stars$12.22-0.4%$12.00-1.8%+86.8%$1.62B$260.11M28.42300Positive NewsWVEWAVE Life Sciences4.7431 of 5 stars$9.74-0.2%$20.27+108.1%+60.4%$1.55B$93.95M-10.82240Positive NewsJANXJanux Therapeutics2.2465 of 5 stars$25.53+1.7%$91.89+259.9%-44.6%$1.51B$10.59M-14.1830Analyst ForecastEWTXEdgewise Therapeutics2.3002 of 5 stars$14.00-1.1%$41.60+197.1%-29.8%$1.49BN/A-9.0360Analyst ForecastARDXArdelyx4.3034 of 5 stars$5.81-2.7%$11.50+97.9%-2.1%$1.44B$386.15M-25.2690HROWHarrow3.6056 of 5 stars$38.32-1.3%$64.67+68.8%-2.7%$1.44B$199.61M-153.28180Analyst RevisionSPRYARS Pharmaceuticals2.4979 of 5 stars$14.03-3.4%$31.00+121.0%-1.9%$1.44B$89.15M-28.6390Analyst Revision Related Companies and Tools Related Companies BHVN Competitors IMCR Competitors CDTX Competitors AUPH Competitors WVE Competitors JANX Competitors EWTX Competitors ARDX Competitors HROW Competitors SPRY Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IVA) was last updated on 8/21/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inventiva S.A. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Inventiva With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access